Genmab A/S
Genmab A/S (GNMSF) Revenue
Annual & quarterly revenue history · segment & region breakdown
GNMSF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsGenmab A/S trailing twelve-month (TTM) revenue is $3.89B, a decrease of 82.11% year-over-year from $3.85B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $3.85B | -$17.67B | -82.11% |
| 2024-12-31 | $21.53B | +$5.05B | +30.67% |
| 2023-12-31 | $16.47B | +$1.97B | +13.57% |
| 2022-12-31 | $14.51B | +$6.02B | +71.01% |
| 2021-12-31 | $8.48B | -$1.63B | -16.11% |
| 2020-12-31 | $10.11B | +$4.75B | +88.43% |
| 2019-12-31 | $5.37B | +$2.34B | +77.38% |
| 2018-12-31 | $3.03B | +$0.66B | +27.89% |
| 2017-12-31 | $2.37B | +$0.55B | +30.25% |
| 2016-12-31 | $1.82B | +$0.68B | +60.29% |
Compare revenue vs peers
BiotechnologyCompare GNMSF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Genmab A/S receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Genmab A/S reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Genmab A/S's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GNMSF revenue · 4 questionsGNMSF's trailing twelve-month (TTM) revenue is $3.89B. That is a decrease of 82.11% year-over-year from $3.85B in FY2025.
▸ Source: FMP · Genmab A/S SEC filings · GAAP · Genmab A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026